This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
Abbott (ABT) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
In the most recent trading session, Abbott (ABT) closed at $134.01, indicating a -1.19% shift from the previous trading day.
NVST vs. ABT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NVST vs. ABT: Which Stock Is the Better Value Option?
Cardiovascular Tailwind Boosts BSX: Here's How to Play the Stock
by Sridatri Sarkar
Boston Scientific rides strong cardiovascular momentum, with booming EP and WATCHMAN sales despite macro headwinds. What is the investment outlook?
Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Abbott (ABT) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Abbott (ABT) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
Abbott (ABT) closed at $132.96 in the latest trading session, marking a -0.56% move from the prior day.
Emerging Markets Power Boston Scientific: Will the Growth Trend Continue?
by Sridatri Sarkar
BSX posts solid Q1 sales growth in emerging markets, reinforcing their role in the company's long-term global strategy.
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Abbott Benefits From Libre & Biosimilars Amid FX, Cost Headwinds
by Zacks Equity Research
ABT sees a 21.6% jump in CGM sales and growing global diagnostics demand, while FX and macro pressure temper its outlook.
Abbott (ABT) Rises Higher Than Market: Key Facts
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $132.85, moving +0.63% from the previous trading session.
Abbott Stock Gains Following FDA Approval of the Tendyne System
by Zacks Equity Research
ABT wins FDA approval for its Tendyne TMVR system, offering a minimally invasive mitral valve replacement for high-risk patients with severe MAC.
The Zacks Analyst Blog Highlights Coca-Cola, Abbott Laboratories and AT&T
by Zacks Equity Research
Coca-Cola, Abbott and AT&T shine in Zacks' latest reports, with each outperforming peers year-to-date despite headwinds in key segments.
Top Stock Reports for Coca-Cola, Abbott & AT&T
by Mark Vickery
Coca-Cola, Abbott, and AT&T beat peers YTD with strong earnings, innovation, and strategic moves, but face headwinds from FX, costs, and competition.
Abbott (ABT) Stock Moves -0.15%: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Abbott (ABT) stood at $131.30, denoting a -0.15% change from the preceding trading day.
Boston Scientific (BSX) Up 3.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Abbott vs. Medtronic: Which Dividend-Paying MedTech Stock is Better?
by Urmimala Biswas
With both MDT & ABT focusing on their core strengths, the stage is set for a compelling comparison. Let's see which stock is poised for greater upside.
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Abbott (ABT) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Abbott Reveals Positive Outcome From REFLECT Studies, Stock Climbs
by Zacks Equity Research
Per REFLECT studies, ABT's Libre technology is the first CGM linked to fewer hospitalizations for heart complications in people with diabetes.
Abbott (ABT) Up 1.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Hims & Hers Stock Declines 3.1% in 3 Months: Is it a Buy Now?
by Debanjana Dey
HIMS is expanding its health and wellness products and services and increasing its focus on AI to solidify its footing. However, macro challenges may hurt performance.
The Zacks Analyst Blog Highlights NVIDIA, Abbott Laboratories, Linde and Tredegar
by Zacks Equity Research
NVIDIA, Abbott Laboratories, Linde and Tredegar are part of the Zacks top Analyst Blog
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
Top Stock Reports for NVIDIA, Abbott Laboratories & Linde
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corp. (NVDA), Abbott Laboratories (ABT) and Linde plc (LIN), as well as a micro-cap stock Tredegar Corp. (TG).